Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


21.12.2019

2 Am J Clin Oncol
1 Arch Bronconeumol
1 Br J Cancer
1 Cancer Lett
4 Clin Lung Cancer
1 Eur J Cancer
1 J Clin Oncol
1 J Thorac Cardiovasc Surg
1 Lancet Oncol
3 Lung Cancer
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. FATEHI HASSANABAD A, Mina F
    Targeting the Mevalonate Pathway for Treating Lung Cancer.
    Am J Clin Oncol. 2020;43:69-70.
    PubMed     Text format     Abstract available

  2. ELEGBEDE AA, Gibson AJ, Fu H, Dean ML, et al
    Real-World Adherence to Guideline-Recommended Treatment for Small Cell Lung Cancer.
    Am J Clin Oncol. 2019 Dec 10. doi: 10.1097/COC.0000000000000657.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  3. GARRIDO-MARTIN EM, Paz-Ares L
    Lung Cancer and Microbiome.
    Arch Bronconeumol. 2019 Dec 10. pii: S0300-2896(19)30240.
    PubMed     Text format    


    Br J Cancer

  4. MCCUTCHAN G, Smits S, Ironmonger L, Slyne C, et al
    Evaluation of a national lung cancer symptom awareness campaign in Wales.
    Br J Cancer. 2019 Dec 16. pii: 10.1038/s41416-019-0676.
    PubMed     Text format     Abstract available


    Cancer Lett

  5. LI Y, Chen F, Shen W, Li B, et al
    WDR74 induces nuclear beta-catenin accumulation and activates Wnt-responsive genes to promote lung cancer growth and metastasis.
    Cancer Lett. 2019 Dec 12. pii: S0304-3835(19)30617.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  6. VAN DE KAMP HJ, Molder MT, Schulkes KJG, Stellingwerf M, et al
    Impact of Lung Cancer Treatment on Cognitive Functioning.
    Clin Lung Cancer. 2019 Jun 15. pii: S1525-7304(19)30148.
    PubMed     Text format     Abstract available

  7. BYEON S, Lee B, Park WY, Choi YL, et al
    Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Clin Lung Cancer. 2019 Nov 21. pii: S1525-7304(19)30323.
    PubMed     Text format     Abstract available

  8. ROGASCH JMM, Furth C, Chibolela C, Hofheinz F, et al
    Validation of Independent Prognostic Value of Asphericity of (18)F-Fluorodeoxyglucose Uptake in Non-Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent.
    Clin Lung Cancer. 2019 Oct 15. pii: S1525-7304(19)30266.
    PubMed     Text format     Abstract available

  9. SKOUGAARD K, Ostrup O, Guldbrandsen K, Sorensen B, et al
    Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER).
    Clin Lung Cancer. 2019 Nov 21. pii: S1525-7304(19)30319.
    PubMed     Text format     Abstract available


    Eur J Cancer

  10. LEIGHL NB, Karaseva N, Nakagawa K, Cho BC, et al
    Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
    Eur J Cancer. 2019;125:49-57.
    PubMed     Text format     Abstract available


    J Clin Oncol

  11. BRADLEY JD, Hu C, Komaki RR, Masters GA, et al
    Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Dec 16:JCO1901162. doi: 10.1200/JCO.19.01162.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  12. RHODIN KE, Rucker AJ, Ready NE, D'Amico TA, et al
    The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.
    J Thorac Cardiovasc Surg. 2019 Dec 10. pii: S0022-5223(19)32182.
    PubMed     Text format     Abstract available


    Lancet Oncol

  13. DRILON A, Siena S, Dziadziuszko R, Barlesi F, et al
    Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30690.
    PubMed     Text format     Abstract available


    Lung Cancer

  14. HELMINEN O, Valo J, Andersen H, Lautamaki A, et al
    Real-world guideline-based treatment of lung cancer improves short- and long-term outcomes and resection rate: A population-based study.
    Lung Cancer. 2019;140:1-7.
    PubMed     Text format     Abstract available

  15. MORITA R, Okishio K, Shimizu J, Saito H, et al
    Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Lung Cancer. 2019;140:8-18.
    PubMed     Text format     Abstract available

  16. BEAU-FALLER M, Pencreach E, Leduc C, Blons H, et al
    Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the
    Lung Cancer. 2019;140:19-26.
    PubMed     Text format     Abstract available


    PLoS One

  17. TRAN LS, Pham HT, Tran VU, Tran TT, et al
    Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
    PLoS One. 2019;14:e0226193.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: